Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants

著者	田谷 正樹
著者別表示	Taya Masaki
journal or publication title	博士論文本文Full
学位授与番号	13301甲第4105号
学位名	博士（医学）
学位授与年月日	2014-09-26
URL	http://hdl.handle.net/2297/41987

doi: <https://doi.org/10.1111/iju.12393>

Original Article: Clinical Investigation**Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants**Masaki Taya,¹ Eitetsu Koh,¹ Kouji Izumi,¹ Masashi Iijima,¹ Yuji Maeda,¹ Tomohiko Matsushita,² Teruaki Iwamoto³ and Mikio Namiki¹¹Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, ²Department of Urology, Ofuna Chuou Hospital, Kamakura, Kanagawa, and ³Division of Male Infertility, Center for Infertility and IVF, International University of Health and Welfare, Nasushiobara, Tochigi, Japan**Abbreviations & Acronyms**

aFT = analog-based free testosterone
AMS = Aging Questionnaire
ASA = American Society of Andrology
cFT = calculated free testosterone
CI = confidence interval
CV = coefficient of variation
DHEA = dehydroepiandrosterone
DHT = dihydrotestosterone
EAA = European Academy of Andrology
EAU = European Academy of Urology
EMAS = the European Male Aging Study
FHS = Framingham Heart Study
FT = free testosterone
iaTT = immunoassay-based total testosterone
ISA = International Society of Andrology
ISSAM = International Society for the Study of the Aging Male
LC-MS/MS = liquid chromatography tandem mass spectrometry
LOH = late-onset hypogonadism
MrOS = Osteoporotic Fractures in Men Study
msTT = liquid chromatography tandem mass spectrometry assay-based total testosterone
NA = not available
RIA = radioimmunoassay
SD = standard deviation
SHBG = sex hormone-binding globulin
TDS = testosterone-deficiency syndrome
TT = total testosterone

Objectives: To determine testosterone fractions in Japanese men and to compare these values with those of Framingham Heart Study participants.**Methods:** We enrolled 498 healthy Japanese men. Total testosterone was assayed by liquid chromatography tandem mass spectrometry, sex hormone-binding globulin was assayed by immunoassay and free testosterone was calculated by a laboratory at the Boston Medical Center. Analog-based free testosterone and immunoassay-based total testosterone were determined by immunoassay. We compared mass spectrometry assay-based total testosterone and calculated free testosterone values in the Japanese participants with values in the American Framingham Heart Study third generation cohort.**Results:** The mean serum mass spectrometry assay-based total testosterone, sex hormone-binding globulin, and calculated free testosterone values were 439.4 ± 167 ng/dL, 65.34 ± 30.61 nmol/L, and 58.75 ± 20.0 pg/mL, respectively. The correlation coefficients with age for mass spectrometry assay-based total testosterone, sex hormone-binding globulin, and calculated free testosterone were 0.0010, 0.5041, and -0.496 , respectively. There were no age-related changes in mass spectrometry assay-based total testosterone values in healthy men ($P = 0.981$), whereas sex hormone-binding globulin and calculated free testosterone levels showed similar age-related changes ($P < 0.0001$). Serum analog-based free testosterone levels (8.24 ± 2.9 pg/mL) showed age-related changes ($P < 0.0001$) regardless of immunoassay-based total testosterone levels ($P = 0.828$). Serum immunoassay-based total testosterone values (486.1 ± 162.5 ng/dL) correlated with serum mass spectrometry assay-based total testosterone values ($r = 0.740$, 95% confidence interval 0.6965–0.7781, $P < 0.0001$). Similarly, analog-based free testosterone and calculated free testosterone values showed a highly significant correlation ($r = 0.706$, 95% confidence interval 0.6587–0.7473, $P < 0.0001$). The analog-based free testosterone values were approximately 10% of the calculated free testosterone values.**Conclusions:** In contrast to the Framingham Heart Study cohort, total testosterone values in Japanese men are not associated with advancing age; thus, they cannot be used to diagnose late-onset hypogonadism in Japan. The analog-based free testosterone value can be considered instead as a suitable biochemical determinant for diagnosing late-onset hypogonadism syndrome.**Key words:** aging, analog free testosterone, late-onset hypogonadism, sex hormone-binding globulin, testosterone.**Introduction**LOH or TDS is a clinical and biochemical syndrome resulting from decreased serum testosterone levels. LOH can negatively impact quality of life and adversely affect multiple organ systems. Accordingly, serum testosterone measurement is the first step in diagnosing LOH and in assessing androgen status.^{1,2}Measurement of TT is generally sufficient for diagnosing androgen excess or deficiency. However, for suspected mild-to-moderate deficiency, measurement of FT is thought to be useful. Currently, several testosterone fractions, including TT, bioavailable testosterone, FT and cFT, can be used to diagnose LOH. Most testosterone is bound to SHBG and to albumin, and, in general, FT is thought to account for only 1–3% of the TT levels. Serum SHBG increases with age and often affects the proportion of testosterone in each fraction.³**Correspondence:** Eitetsu Koh M.D., Ph.D., Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8641, Japan. Email: kohei@med.kanazawa-u.ac.jpReceived 24 August 2013; accepted 11 December 2013.
Online publication 9 January 2014

Although isotope dilution equilibrium dialysis is recommended for accurate FT measurement, this method is time-consuming and is associated with technical difficulties. An alternative is analog immunoassays, which are available for detecting FT levels in clinical settings. However, analog immunoassays have been widely criticized for their lack of accuracy and for the variability of results with fluctuating SHBG concentrations.^{4,5} These qualities suggest that the immunoassays do not truly measure FT. A third alternative is to calculate FT using equations based on the law of mass action.^{6–8}

Many studies have evaluated age-related changes in serum testosterone fractions in healthy men. However, just two major studies have evaluated the testosterone levels in community-dwelling men in Japan. Iwamoto *et al.*⁹ reported reference values for serum iaTT and serum aFT, whereas Okamura *et al.*¹⁰ analyzed the serum levels of iaTT and cFT using RIA; iaTT in community-dwelling men. Interestingly, neither study found that serum TT declined with age in Japanese men, in contrast with declines in FT with age.

However, other cross-sectional studies did show a decrease in serum TT concentration with age.^{11,12} Longitudinal studies, the Massachusetts Male Aging Study¹³ and the Baltimore Longitudinal Aging Study¹⁴ all reported decreases in TT with increasing age. Circulating testosterone in men is thought to decline progressively by 0.4–2% per year from the third decade onward.¹⁵ In addition, the ISA, ISSAM, EAU, EAA and ASA recommend measuring serum TT to establish a diagnosis of hypogonadism.

In contrast, the FHS is a long-term, ongoing cardiovascular study of residents of the town of Framingham, Massachusetts, USA. The study began in 1948 with 5209 adult participants from Framingham, and is now on its third generation of participants. The FHS participants, and their children and grandchildren, voluntarily consented to undergo a detailed medical history, physical examination and medical tests every 2 years, creating a wealth of data about physical and mental health, especially about cardiovascular disease. Hormonal profile is available for that study.

The present study used LC-MS/MS, immunoassay and calculation to determine the testosterone fraction values in Japanese men aged over 40 years. To investigate whether there are ethnic differences in testosterone levels according to age, the data from the FHS participants and Japanese participants were compared.

Methods

Patients and samples

The present study was approved by the Ethics Committee of the Kanazawa University Graduate School of Medical Science (approval no. 40-H19). This cross-sectional study is part of the project, “Clinical trial about the utility of the androgen replacement therapy in late-onset hypogonadism syndrome” from 2007 to 2010. That study consisted of screening for healthy men and a following intervention study of the candidates.

A total of 1682 participants were enrolled in the present screening study and sera were obtained from all participants. Of the 1682 participants, 498 were intentionally selected from three areas, because enough of the sera in three groups could be

sent to the Hormone Assay Laboratory (Boston University School of Medicine, Boston Medical Center, MA, USA) for assay of hormonal parameters.

A total of 131, 92 and 275 participants, which were all ethnically Japanese, were enrolled in Ishikawa (Kanazawa city), Kanagawa (Kamakura city) and Tochigi (Nasushiobara city) prefecture and the surrounding area, respectively.

A total of 131 participants were invited to participate in the present study during their regular visits to a urologist and general internist. The volunteers had no history of the presence of any cancers and/or urinary retention as a result of benign prostatic hyperplasia. Exclusion criteria included cirrhosis or any other liver disease as well as serious psychiatric disorders, use of mood stabilizers, psychotropic and anxiolytic agents, as well as medications known to affect the endocrine system and hypothyroidism. Blood samples were obtained between 08.00 hours and 10.00 hours.

Sera of 92 and 275 participants, who had a medical check-up for a clinical survey of healthy men, were obtained. The blood samples of these 367 participants were obtained at approximately 08.00 hours in the morning.

The present study was funded as part of the Longevity Sciences study (grant no. H19-CHOJU-003, 1900000) by the Ministry of Health, Labor and Welfare, Japan.

TT, FT and SHBG measurements

Blood samples were immediately centrifuged at 4°C. The serum was stored at –80°C until assays were carried out. Part of each serum sample was sent to the Hormone Assay Laboratory for TT, SHBG and cFT determinations in March 2012.

TT was assayed using the msTT. The functional limit of detection, defined as the lowest concentration and detected with less than 20% CV, was 2 ng/dL; no sample was outside the linear range of 2–2000 ng/dL. Recovery was calculated by adding known amounts of testosterone to charcoal-stripped serum samples and analyzing the samples by LC-MS/MS. The correlation between the amount added and the amount measured by LC-MS/MS was 0.998. The average recovery was $102 \pm 3\%$. The cross-reactivity of DHEA, DHEAS, DHT, androstenedione and estradiol in the testosterone assay was negligible at 10-fold the circulating concentrations of these hormones. The interassay coefficient of variation was 15.8% at 12.0 ng/dL, 10.6% at 23.5 ng/dL, 7.9% at 48.6 ng/dL, 7.7% at 241 ng/dL, 4.4% at 532 ng/dL and 3.3% at 1016 ng/dL.¹⁶ Reference ranges were not shown in the test report.

FT was calculated using a published law-of-mass-action equation that utilizes an association constant estimated from a systematic review of published binding studies and an iterative numerical method.¹⁷ The intra- and interassay coefficients of variation in the low, medium and high pools were 4.3% and 5.5%, 4.9% and 2.4%, and 8.1% and 2.5%, respectively. Reference ranges were not shown in the test report.

SHBG levels were measured using a two-site immuno-fluorometric assay (DELFI-Wallac, Turku, Finland).^{18,19} The interassay CV were 8.3%, 7.9% and 10.9%, and the intra-assay CV were 7.3%, 7.1%, and 8.7%, respectively, for the low, medium and high pools. The analytical sensitivity of the assays was 0.5 nmol/L. Reference ranges were shown as 12.9–61.7 nmol/L in the test report.

Fig. 1 Distribution of participants according to age by decade.

Comparison of TT and FT levels with the levels in FHS participants

This current project is based on that longitudinal study. The testosterone levels according to age were compared in Japanese participants versus FHS participants; the FHS data is referred to in Tables S1 and S2 in the literature for comparison.¹⁶ The testosterone determinations were measured using the same assay as in the current study.

Analog TT and FT measurements

Aliquots of each serum sample were sent to a laboratory (SRL, Tokyo, Japan) for TT and aFT measurement. The iaTT was measured with a commercial chemiluminescent immunoassay (Architect Testosterone kit; Abbott Japan, Tokyo, Japan), and aFT was measured using a kit from Diagnostic Products (Los Angeles, CA, USA). The interassay CV were less than 15% for both kits according to the manufacturer information.

Statistical analysis

Data were analyzed using GraphPad Prism version 5.04 for Windows (GraphPad Software, San Diego, CA, USA; <http://www.graphpad.com>). Parameter values are reported as means and SD. Correlations between the immunoassay and mass spectroscopic values were determined using Pearson's correlations. Correlations of serum msTT and serum iaTT or serum aFT and serum cFT were determined using Pearson's simple and partial correlation coefficients. Differences were considered statistically significant at $P < 0.05$.

Results

Participants

Initially, 498 men were enrolled in the study. The mean participant age was 60.5 ± 12.9 years (median 60 years, range 40–90 years). The distribution of participants by age is shown in Figure 1. Of the 498 participants, the iaTT of 20 could not be assayed, as the sample volumes were insufficient. The mean age of the cohort after exclusion of these 20 participants ($n = 478$) was 60.6 ± 13.0 years (median 59 years, range 40–90 years).

Testosterone and SHBG according to age

The mean serum msTT value was 439.4 ± 167 ng/dL (range 139.4–1378 ng/dL, $n = 498$), and the median value was 420 ng/dL (Fig. 2a). The mean serum SHBG value was 65.34 ± 30.61 nmol/L (range 10.70–233.8 nmol/L, $n = 498$), and the median value was 59.55 nmol/L (Fig. 2b). The mean cFT value was 58.75 ± 20.0 pg/mL (range 16.0–150.8 pg/mL, $n = 498$), and the median value was 56.90 pg/mL (Fig. 2c). These three determinations were carried out by the Hormone Assay Laboratory at Boston University.

Serum msTT levels showed no significant decrease with increasing age in healthy men ($P = 0.981$). The correlation coefficient with age for serum msTT level was 0.0010 (95% CI -0.08684 – 0.08894). In contrast, the correlation coefficients with age for serum SHBG and cFT levels were 0.5041 (95% CI 0.4355–0.5668) and -0.496 (95% CI -0.5619 to -0.4295), respectively. These correlations were significantly different for age ($P < 0.0001$). Even though the serum msTT level showed no age-related changes, serum SHBG and serum cFT levels showed very similar age-related changes.

Comparison of serum msTT and serum cFT between the FHS and in the present study according to age

Figure 3 shows the relationships of serum msTT and cFT values in the FHS cohort and in the present cohort according to participant age with age stratified by decade. Even though the mean serum msTT did not decline with age in the current cohort, TT was associated inversely with age in the FHS broad sample.¹⁶ The mean serum msTT value in the current samples was approximately 70–80% lower than the mean value in the FHS cohort (Fig. 3a). Furthermore, the cFT values decreased with age in both groups. The mean cFT value in the current cohort was approximately 60–70% lower than in the FHS broad sample (Fig. 3b).

Comparison of serum iaTT and serum aFT according to age

The mean serum iaTT value was 486.1 ± 162.5 ng/dL (range 135.0–1100 ng/dL, $n = 478$), and the median value was 472.0 ng/dL (Fig. 2d). The mean serum aFT value was 8.25 ± 2.9 pg/mL (range 21.5–1.90 pg/mL, $n = 498$), and the median value was 8.1 pg/mL (Fig. 2e). Serum iaTT levels showed no significant decrease with increasing age in healthy men ($P = 0.828$). The correlation coefficient with age for the serum iaTT level was 0.0102 (95% CI -0.0796 – 0.0998). In contrast, the correlation coefficient with age for serum aFT levels was -0.458 (95% CI -0.525 to -0.3861). The correlation was significantly different in age ($P < 0.0001$). The serum iaTT level showed no age-related change, whereas the serum aFT levels in both cohorts showed very similar age-related changes.

Correlation analysis of serum msTT and serum iaTT

Serum iaTT measurements were moderately correlated with the corresponding measurements of serum msTT (Pearson's $r = 0.740$, 95% CI 0.6965–0.7781, $P < 0.0001$, $n = 478$). The scatter plot in Figure 4a shows the high correlation between

Fig. 2 Scatter blots showing the results of (a) msTT, (b) SHBG, (c) cFT, (d) iaTT (e) and aFT according to participant age.

Fig. 3 Comparison of the FHS cohort and the present study cohort using (a) serum msTT and (b) cFT according to participant age. The filled circles in red and squares in green represent FHS and current participants, respectively. Vertical lines indicate the standard deviation. Modified from Bhasin *et al.* with permission¹⁶

Fig. 4 Correlation analysis. (a) Serum TT determined using iaTT and msTT and (b) aFT and cFT. In each panel, the solid line indicates the regression relationship and the dashed line represents a slope of unity. The ratio of Y to X is (a) 1.0 and (b) 0.1, respectively.

analog and LC-MS/MS measurements; the serum iaTT values were higher than the serum msTT values, as many samples were over the unity line. The mean serum msTT value (439.4 ± 166.7 ng/dL) was approximately 90% lower than that of serum iaTT (486.1 ± 162.5 ng/dL), and this

difference was significant ($P < 0.0001$; Table 1). Thus, LC-MS/MS results in significantly lower serum testosterone values than those determined by immunoassay; this could be as a result of substances that interfere with the immunoassay determination.^{20,21}

Table 1 TT levels reported in Japanese studies

Age range (years)	20–29	30–39	40–49	50–59	60–69	70–79	80+	Total (n)
Iwamoto <i>et al.</i>	294	287	235	169	120	38	NA	1143
	mean (+2SD, –2SD) ng/mL	4.98 (8.36, 2.47)	4.3 (7.16, 2.17)	3.91 (6.74, 1.84)	3.83 (6.61, 1.8)	3.84 (6.46, 1.9)	NA	4.32 (7.5, 2.01)
Okamura <i>et al.</i>	NA	NA	287	278	276	279	NA	1120
	mean ± SD ng/mL	NA	5.00 ± 2.94	5.12 ± 3.28	4.99 ± 3.20	5.45 ± 3.56	NA	5.13 ± 3.26
Present study	NA	NA	121	125	90	99	43	478
	mean ± SD ng/mL	NA	4.76 ± 1.68	5.02 ± 1.50	4.66 ± 1.57	5.04 ± 0.17	4.69 ± 1.68	4.86 ± 1.63
	msTT (n)	NA	124	131	98	102	43	498
	mean ± SD ng/mL	NA	4.34 ± 1.70	4.47 ± 1.53	4.28 ± 1.82	4.54 ± 1.71	4.23 ± 1.50	4.39 ± 1.67

Correlation analysis between serum aFT and serum cFT

Serum aFT values were moderately correlated with cFT values (Pearson's $r = 0.706$, 95% CI 0.6587–0.7473, $P < 0.0001$, $n = 498$). When using aFT values versus cFT values, it is important to note the strong and highly significant correlation of these two assays. As reported previously, the aFT values are lower than the cFT values.²² In the present study, the regression equation was $Y = 0.1017X + 2.270$. The values for aFT were also lower by approximately 10% than the cFT values (Fig. 4b). As shown in Figure 4b, the slope of regression shifted upwards.

Discussion

LOH, also referred to as age-associated TDS, has specific clinical and biochemical features. Accurate testosterone level determination is essential for the diagnosis of LOH. Bhasin *et al.* determined the reference limits for TT and FT concentrations in a community-based sample of healthy men who were aged 19–40 years using data from the FHS third generation cohort.

The FT level was calculated. Values below the 2.5th percentile of the reference sample ($n = 456$) were considered low testosterone values. The 2.5th percentile values were 348.3 ng/dL for TT and 70.0 pg/mL for FT. They showed that values below the proposed lower reference limits were associated with increased risks for conditions that were previously associated with androgen deficiency in one or more cohorts.^{18,23}

One large study carried out in 1143 community-dwelling Japanese men aged 20–77 years generated reference testosterone ranges. Specifically, Iwamoto *et al.* determined serum iaTT and serum aFT levels using RIA (iaTT).⁹ In a second study, Okamura *et al.* analyzed the levels of serum TT and cFT in 1120 community-dwelling Japanese men aged 40–79 years using RIA (iaTT); however, they could not use the term “reference ranges” in their study, because they did not follow the formal procedures to determine reference ranges as proposed by the National Committee for Clinical Laboratory Standards. Nevertheless, their serum samples were from community-dwelling men and the determined values were used to evaluate LOH.

Table 1 shows the serum iaTT values in the three studies carried out in Japan. The serum iaTT values did not decrease with age in any of these studies. The mean serum iaTT values according to age by decade in Iwamoto's study were lower than those in the Okamura *et al.* study and in the current study, even though the same assay was used.

Although different commercially available assay kits might give different testosterone values, it appears that the mean serum iaTT value (4.37 ng/mL) is relatively lower in Iwamoto's study, which determined testosterone levels in healthy community-dwelling men. The serum iaTT values in the Iwamoto study and the current study were (mean [+2SD to –2SD]) 4.32 ng/mL (7.5–2.01 ng/mL) and (mean ± SD) 486.1 ± 162.5 ng/dL (4.86 ± 1.63 ng/mL), respectively. As the mean value as determined in the Iwamoto study was relatively low, it is likely to produce bias inclusion of men aged in their 20s and 30s. In fact, we did not measure the values in men aged in their 20s and 30s, who are likely to have higher testosterone values.

In the current study, the serum iaTT values were higher than the serum msTT values in men aged 40–80 years or older. Figure 3a shows the serum msTT in the FHS and current cohorts according to age by decade. The serum msTT value in the current sample was approximately 70–80% lower than that of the FHS broad sample. The distribution of TT levels by decades of age was 10–20% higher in the FHS than in the other two cohorts (the MrOS and the EMAS cohorts).¹⁶ A study of an age-stratified, random sample of Rochester (MN, USA) men aged 22–93 years included 325 men, with approximately 50 men per decade. The means serum msTT and iaTT values were 467.8 ± 173.4 ng/dL and 492.9 ± 196.2 ng/dL.²⁴ The TT values in the current cohort is nearly the same as these in three cohorts. Therefore, it appears likely that the values of msTT in the FHS samples were actually higher contrary to expectations.

There is considerable controversy regarding the best method for measuring FT. Although equilibrium dialysis is widely accepted as the ‘gold standard’ for measuring FT,²⁵ it is considered laborious, slow and costly.²⁶ There are few laboratories that assay FT using the equilibrium dialysis method in Japan. To evaluate FT, the Iwamoto study used an analog FT assay, the Okamura study utilized the equilibrium-binding theory using TT, SHBG and albumin values,⁶ and the current study utilized the law-of-mass-action equation as described in the Materials and Methods.¹⁷

Table 2 shows the FT values determined in the three studies carried out in Japan. All three studies found that serum aFT and cFT levels decreased with age (Fig. 2c). The mean serum aFT values according to age by decade in the current cohort were lower than those in the Iwamoto study; both studies used the same detection kit. The mean cFT values according to age by decade in the current cohort were also lower than those in the Iwamoto study, and the mean aFT values according to age by decade in the current cohort were lower than those in the Okamura study. Figure 3b shows that the cFT values in the current cohort were approximately 70–80% lower than in the FHS broad sample. The FT values according to age by decade were 10–20% higher in the FHS cohort than in the other two cohorts (i.e. the MrOS and the EMAS cohorts).¹⁶ Therefore, it is likely that the cFT values in the FHS cohort were higher.

There is general agreement that approximately 44% of the circulating testosterone is strongly bound to SHBG, 54% is loosely bound to albumin and 2% is present as free hormone.^{2,27,28} The mean values of serum SHBG according to age by decade in the current study were very high compared with those determined in participants in a cross-sectional study of 400 independently-living European and American men aged between 40 and 80 years.²⁹

The mean SHBG values by decade of age were 34.7 nmol/L for men aged in their 40s, 38.0 nmol/L for men aged in their 50s, 43.6 nmol/L for men aged in their 60s and 46.1 nmol/L for men aged in their 70s. The participants of the Rochester study had a median serum SHBG value of 33.3 nmol/L (quartiles: 24.9–48.3 nmol/L).²⁴ The mean SHBG values by decade were approximately twice those of the current sample compared with values reported in the literature (Table 2).

Biological factors, such as interindividual variability or ethnic factors, could account for this variation. It is unclear why SHBG levels increase with age, but age-associated decreases in

Table 2 FT level and SHBG reported in Japanese studies

Age range	20–29	30–39	40–49	50–59	60–69	70–79	80+	Total (n)
Iwamoto et al.	294	287	235	169	120	38	NA	1143
	mean (+2SD, –2SD) pg/mL	16.8 (27.9, 8.5)	14.3 (23.1, 7.6)	12.0 (18.4, 6.9)	10.3 (16.7, 5.4)	8.5 (13.8, 4.5)	NA	8.5 (13.8, 4.5)
Okamura et al.	NA	NA	127	121	102	121	NA	471
	mean $\pm$ SD pg/mL	NA	15.1 $\pm$ 8.4	13.9 $\pm$ 6.8	12.0 $\pm$ 6.6	11.5 $\pm$ 7.0	NA	13.2 $\pm$ 7.8
	cFT (n)	NA	127	121	102	121	NA	471
	mean $\pm$ SD pg/mL	NA	88.2 $\pm$ 43.8	82.3 $\pm$ 35.8	70.9 $\pm$ 38.8	65.0 $\pm$ 38.8	NA	77.0 $\pm$ 43.4
Present study	NA	NA	121	125	90	99	43	478
	aFT (n)	NA	9.74 $\pm$ 2.29	9.00 $\pm$ 2.29	7.89 $\pm$ 2.69	7.00 $\pm$ 2.35	5.48 $\pm$ 2.24	8.25 $\pm$ 2.89
	mean $\pm$ SD pg/mL	NA	121	125	90	99	43	478
	cFT (n)	NA	70.2 $\pm$ 20.1	65.4 $\pm$ 18.2	53.4 $\pm$ 15.9	49.7 $\pm$ 14.7	39.6 $\pm$ 13.6	58.8 $\pm$ 20.1
	SHBG (n)	NA	121	125	90	99	43	478
	mean $\pm$ SD nmol/L	NA	48.4 $\pm$ 20.2	56.2 $\pm$ 26.4	68.0 $\pm$ 28.8	80.3 $\pm$ 28.6	97.9 $\pm$ 31.5	65.2 $\pm$ 30.5

GH and IGF-I levels might contribute to the increase.³⁰ However, SHBG measurements were strikingly different in different studies, so differences might be due in part to inaccurate measurements.

In conclusion, the present large cross-sectional study showed that the TT level did not decrease with age in this Japanese cohort, in contrast to findings in the FHS cohort. Thus, the TT level cannot be used to diagnose LOH in Japan, even though it is recommended for use in European and American populations. However, the aFT can be used as a convenient biochemical determinant for diagnosing LOH syndrome in Japanese men. Future studies should consider that these determinants and SHBG might impact the associations between circulating testosterone fractions and associated clinical conditions. Furthermore, these determinants could be used to define target populations for male hormone replacement therapy.

Acknowledgments

We are grateful for the academic discussions with Professor Shalender Bhasin (Boston University School of Medicine, Sections of Endocrinology, Diabetes, and Nutrition).

Conflict of interest

None declared.

References

- Wang C, Nieschlag E, Swerdloff RS *et al.* ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. *Aging Male* 2009; **12**: 5–12.
- Namiki M, Akaza H, Shimazui T *et al.* Clinical practice manual for late-onset hypogonadism syndrome. *Int. J. Urol.* 2008; **15**: 377–88.
- Morley JE, Kaiser FE, Perry HM III *et al.* Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metabolism* 1997; **46**: 410–13.
- Rosner W. Errors in the measurement of plasma free testosterone. *J. Clin. Endocrinol. Metab.* 1997; **82**: 2014–15.
- Fritz KS, McKean AJ, Nelson JC, Wilcox RB. Analog-based free testosterone test results linked to total testosterone concentrations, not free testosterone concentrations. *Clin. Chem.* 2008; **54**: 512–16.
- Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J. Clin. Endocrinol. Metab.* 1999; **84**: 3666–72.
- de Ronde W, van der Schouw YT, Pols HA *et al.* Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. *Clin. Chem.* 2006; **52**: 1777–84.
- Ho CK, Stoddart M, Walton M, Anderson RA, Beckett GJ. Calculated free testosterone in men: comparison of four equations and with free androgen index. *Ann. Clin. Biochem.* 2006; **43**: 389–97.
- Iwamoto T, Yanase T, Horie H, Namiki M, Okuyama A. Late-onset hypogonadism (LOH) and androgens: validity of the measurement of free testosterone levels in the diagnostic criteria in Japan. *Int. J. Urol.* 2009; **16**: 168–74.
- Okamura K, Ando F, Shimokata H. Serum total and free testosterone level of Japanese men: a population-based study. *Int. J. Urol.* 2005; **12**: 810–14.
- Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. *J. Clin. Endocrinol. Metab.* 1984; **59**: 955–62.
- Araujo AB, O'Donnell AB, Brambilla DJ *et al.* Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J. Clin. Endocrinol. Metab.* 2004; **89**: 5920–6.
- Feldman HA, Longcope C, Derby CA *et al.* Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. *J. Clin. Endocrinol. Metab.* 2002; **87**: 589–98.
- Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. *J. Clin. Endocrinol. Metab.* 2001; **86**: 724–31.
- Tajar A, Forti G, O'Neill TW *et al.* Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. *J. Clin. Endocrinol. Metab.* 2010; **95**: 1810–18.
- Bhasin S, Pencina M, Jasuja GK *et al.* Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. *J. Clin. Endocrinol. Metab.* 2011; **96**: 2430–9.
- Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. *Steroids* 2009; **74**: 512–19.
- Krasnoff JB, Basaria S, Pencina MJ *et al.* Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. *J. Clin. Endocrinol. Metab.* 2010; **95**: 2790–9.
- Bhasin S, Woodhouse L, Casaburi R *et al.* Testosterone dose-response relationships in healthy young men. *Am. J. Physiol. Endocrinol. Metab.* 2001; **281**: E1172–81.
- Janse F, Eijkemans MJ, Goverde AJ *et al.* Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. *Eur. J. Endocrinol.* 2011; **165**: 925–33.
- Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. *J. Clin. Endocrinol. Metab.* 2004; **89**: 534–43.
- Moreno SA, Shyam A, Morgentaler A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. *J. Sex. Med.* 2010; **7**: 1948–53.
- Haring R, Teng Z, Xanthakis V *et al.* Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. *Clin. Endocrinol. (Oxf.)* 2013; **78**: 629–34.
- Khosla S, Amin S, Singh RJ, Atkinson EJ, Melton LJ III, Riggs BL. Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density. *Osteoporos. Int.* 2008; **19**: 1465–71.
- Wang C, Nieschlag E, Swerdloff R *et al.* Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. *Eur. J. Endocrinol.* 2008; **159**: 507–14.
- Ly LP, Sartorius G, Hull L *et al.* Accuracy of calculated free testosterone formulae in men. *Clin. Endocrinol. (Oxf.)* 2010; **73**: 382–8.
- Lepage R. Measurement of testosterone and its sub-fractions in Canada. *Clin. Biochem.* 2006; **39**: 97–108.
- Yamamoto K, Koh E, Matsui F *et al.* Measurement-specific bioavailable testosterone using concanavalin A precipitation: comparison of calculated and assayed bioavailable testosterone. *Int. J. Urol.* 2009; **16**: 894–901.
- Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40–80 years. *Eur. J. Endocrinol.* 2003; **149**: 583–9.
- Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. *J. Clin. Endocrinol. Metab.* 1996; **81**: 1821–6.